Skip to content
OpenCapital
Get started

Organon OGN Other — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Regeneron Pharmaceuticals logo
REGNOther products — Revenue
$31.3M—
Bristol-Myers Squibb logo
BMYOther revenues — Total Revenues
$227M0.0%
Eli Lilly logo
LLYOther — Revenue
$187M-12.2%
Cleveland-Cliffs logo
CLFOther — Revenue
$617M+7.7%
Gilead Sciences logo
GILDOther — Total revenues
$58M-17.1%
Amgen logo
AMGNOther products — Total revenues
$1.53B+3.6%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%
Enterprise value$10.98B-26.4%
P/E6.6×+2.1×
P/S0.6×-0.8×

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's other — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's other — revenue?
Organon (OGN) reported other — revenue of $87M in Q1 2026.
How has Organon's other — revenue changed year-over-year?
Organon's other — revenue increased by 11.5% year-over-year, from $78M to $87M.
What is the long-term trend for Organon's other — revenue?
Over 4 years (2021 to 2025), Organon's other — revenue has grown at a -1.6% compound annual growth rate (CAGR), from $360M to $338M.
What does other — revenue mean?
This metric tracks revenue derived from a collection of established pharmaceutical brands that are not categorized within the company's core strategic therapeutic areas. These products typically represent mature assets that contribute to cash flow stability rather than primary growth. Analyzing this metric allows stakeholders to evaluate the revenue contribution and lifecycle management of the company's legacy product portfolio.